anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Alzheimer's disease (AD) is the most common form of dementia. Aberrant regulation of microRNAs (miRNAs) has been implicated in the pathogenesis of AD. In a large case-control study recruiting 208 patients with AD and 205 elderly control subjects, miRNA-let-7d-5p attracted our attention for its downregulated level in patients with AD. However, the biological functions of let-7d-5p in AD pathogenesis have not been investigated. This study emphasized the functions and mechanisms of let-7d-5p in the pathogenesis of AD. Mouse microglial BV2 cells treated with amyloid-β (Aβ)1-42 were used as in vitro AD inflammation models. We reported that let-7d-5p was downregulated in Aβ1-42-stimulated BV2 cells, and upregulation of let-7d-5p promoted the transversion of microglial cells from Ml phenotype to M2 phenotype. Then, the binding relationship between let-7d-5p and Map3k1 was verified by luciferase reporter assays. Mechanistically, let-7d-5p could target Map3k1 3'UTR to inactivate ERK/p38 MAPK signaling. Therefore, it was suggested that let-7d-5p might be a novel modulator of microglial neuroinflammation and serve as a novel target for diagnosis and treatment of AD.
A balloon catheter assembly for delivering nano-carriers to bifurcation lesions in one or more of a main branch and a side branch of a blood vessel bifurcation within 30 to 90 seconds is provided. The balloon catheter assembly includes two or more balloons designed for use in the blood vessel bifurcation. The balloon catheter assembly may also include one or more stents. A surface of one or more of the two or more balloons is coated with the nano-carriers. Stents, when included, may also be coated with the nano-carriers. The nano-carriers include one or more drugs encapsulated with one or more biological agents.
All recruited participants will perform 6 weeks of resistance training with the same volume. The total training volume (sets x repetitions) will be 232 repetitions in the leg press and 160 repetitions in the chest press, with relative intensities ranging from 40% to 70% of 1RM.
The WHI enrolled approximately 11,000 predominantly healthy postmenopausal women to assess the risks and benefits of daily oral conjugated estrogens 0.625 mg compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD death), with invasive breast cancer as the primary adverse outcome. A "global index" included the earliest occurrence of CHD, invasive breast cancer, stroke, PE, colorectal cancer, hip fracture, or death due to other cause. These substudies did not evaluate the effects of conjugated estrogens on menopausal symptoms.

The WHI estrogen-alone substudy was stopped early because an increased risk of stroke was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints.

Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow- up of 7.1 years are presented in Table 6.

For those outcomes included in the WHI "global index" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more strokes, while the absolute risk reduction per 10,000 women-years was 7 fewer hip fractures. The absolute excess risk of events included in the "global index" was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality.

No overall difference for primary CHD events (nonfatal MI, silent MI and CHD death) and invasive breast cancer incidence in women receiving conjugated estrogens-alone compared to placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years.

Centrally adjudicated results for stroke events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant differences in distribution of stroke subtype or severity, including fatal strokes, in women receiving conjugated estrogens-alone compared to placebo. Estrogen-alone increased the risk for ischemic stroke, and this excess risk was present in all subgroups of women examined.

Timing of the initiation of estrogen-alone therapy relative to the start of menopause may affect the overall risk benefit profile. The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [hazard ratio (HR) 0.63 (95 percent CI, 0.36–1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46–1.11)].
Method and apparatus for monitoring a patient having a tumor to determine perfusion tumor heterogeneity wherein a solution containing a tracer, preferably a  2 H-saline solution is infused into the patient's bloodstream at a predetermined slow rate to effect perfusion into the tumor. An MRI machine is adjusted to acquire a set of dynamic  2 H magnetic resonance images of the tumor. The  2 H-images are obtained before infusion, during infusion and post infusion. First, the obtained images are processed to quantitatively determine perfusion per voxel of the images. Next, maps of perfusion parameters are generated to indicate spatial distribution of tumor perfusion. The maps are displayed in color code and analyzed.
Traumatic brain injury (TBI) is a leading cause of long-term disability across the world. Evidence for the usefulness of imaging and fluid biomarkers to predict outcomes and screen for the need to monitor complications in the acute stage is steadily increasing. Still, many people experience symptoms such as fatigue and cognitive and motor dysfunction in the chronic phase of TBI, where objective assessments for brain injury are lacking. Consensus criteria for traumatic encephalopathy syndrome, a clinical syndrome possibly associated with the neurodegenerative disease chronic traumatic encephalopathy, which is commonly associated with sports concussion, have been defined only recently. However, these criteria do not fit all individuals living with chronic consequences of TBI. The pathophysiology of chronic TBI shares many similarities with other neurodegenerative and neuroinflammatory conditions, such as Alzheimer disease. As with Alzheimer disease, advancements in fluid biomarkers represent one of the most promising paths for unravelling the chain of pathophysiological events to enable discrimination between these conditions and, with time, provide prediction modelling and therapeutic end points. This Review summarizes fluid biomarker findings in the chronic phase of TBI (≥6 months after injury) that demonstrate the involvement of inflammation, glial biology and neurodegeneration in the long-term complications of TBI. We explore how the biomarkers associate with outcome and imaging findings and aim to establish mechanistic differences in biomarker patterns between types of chronic TBI and other neurodegenerative conditions. Finally, current limitations and areas of priority for future fluid biomarker research are highlighted.
The invention provides a microcapsule feed additive resisting to litopenaeus vannamei pathogenic vice hemolysis vibrio. The additive is composed of litopenaeus vannamei pathogenic vice hemolysis vibrio egg yolk antibody freeze-dried powder, astragalus powder and beta-cyclodextrin. The litopenaeus vannamei pathogenic vice hemolysis vibrio egg yolk antibody freeze-dried powder is mainly used for lowering or eliminating the possibility that the litopenaeus vannamei is infected by the vice hemolysis vibrio. The astragalus powder is used for improving the immunity of the litopenaeus vannamei. The beta-cyclodextrin is mainly used for making the egg yolk antibody freeze-dried powder play the embedding slow-release effect. According to the additive, spray drying is conducted on the obtained litopenaeus vannamei pathogenic vice hemolysis vibrio egg yolk antibody freeze-dried powder with the valence of the antibody reaching 211, the astragalus powder and the beta-cyclodextrin, microcapsule dry powder is obtained, the microcapsule feed additive and litopenaeus vannamei feed sold on the market are used for feeding litopenaeus vannamei together according to a certain proportion, the diseases caused by the pathogenic vice hemolysis vibrio can be prevented and treated in the breeding period of the litopenaeus vannamei, the breeding survival rate of the litopenaeus vannamei is raised, and the economic benefits of litopenaeus vannamei breeding and production are remarkably increased; the problem that at present the red body disease is caused by the vice hemolysis vibrio easily in the litopenaeus vannamei breeding and production processes is solved.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In controlled clinical studies of 425 Desonide Gel, 0.05%-treated subjects and 157 Vehicle-treated subjects, adverse events occurred at the application site in 3% of subjects treated with Desonide Gel, 0.05% and the incidence rate was not higher compared with vehicle-treated subjects. The most common local adverse events in Desonide Gel, 0.05% treated subjects were application site burning in 1% (4/425) and rash in 1% (3/425) followed by application site pruritus in <1% (2/425).

Adverse events that resulted in premature discontinuation of study drug in Desonide Gel, 0.05% treated subjects were telangiectasia and worsening of atopic dermatitis in one subject each. Additional adverse events observed during clinical trials for patients treated with Desonide Gel, 0.05% included headache in 2% (8/425) compared with 1% (2/157) in those treated with vehicle.

The following additional local adverse reactions have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.
PURPOSE:To obtain water-repellent powders which have surfaces having improved wettability and improved penetrability and are uniformly coated in a short time, by mixing a powder with a treating soln. composed of a fluorohydrocarbon contg. a water-repelling agent and removing the fluorohydrocarbon. CONSTITUTION:A powder is mixed with a treating soln. composed of a fluorohydrocarbon contg. a water-repelling agent and having a surface tension of 20dyn.cm<-1> under pressure and/or under low temp. conditions. The fluorohydrocarbon is removed from the mixture under atmospheric pressure and/or under elevated temp. conditions to coat uniformly the surface of the powder with the water-repelling agent. If desired, a baking treatment is carried out at a high temp. to obtain the desired powder. Preferred examples of the water-repelling agents are methylhydrogenpolysiloxane, dimethylpolysiloxane, methylphenylpolysiloxane and mixtures thereof from the viewpoints of compati bility with the fluorohydrocarbon, the degree of water repellency of the resulting water-repellent powder and organoleptic properties such as touch feeling.
In certain embodiments, an ophthalmic system and computer-implemented method for analyzing multiple spectral information to generate ophthalmic information are described. In an exemplary ophthalmic system, multiple spectral information associated with an eye of a patient is captured via an imaging system. A first set of information and a second set of information are extracted from the multiple spectral information. A visualization of the multiple spectral information is generated using the first set of information. The first set of information and the second set of information are evaluated using different deep learning models to generate ophthalmic information. The ophthalmic information is sent to a user for diagnostic evaluation.
The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I?B.alpha., I?B.alpha.  kinase. In particular, the present invention relates to the purified kinase, purified polypeptide subunits of the kinase, nucleic acid molecules coding for the purified polypeptide subunits; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to the kinase or its polypeptide subunits; hybridomas containing the antibodies; nucleic acid probes for the detection of the nucleic acid encoding the kinase; a method of detecting nucleic acids encoding the kinase or polypeptides of the kinase in a sample; and kits containing nucleic acid probes or antibodies. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-?B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase or polypeptides of the kinase of this invention to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase and to structure-based design of ligands, agonists, and antagonists of the kinase. This invention further relates to gene therapy using the nucleic acids of the invention.
The humanized antibody against Yersinia pestis antigen F1 and its application, the light chain variable region of the antibody has SEQ ID NO 1 nucleotide sequence and SEQ ID NO 2 amino acid sequence, wherein the light chain hypervariable region sequence has SEQ ID NO 3, SEQ ID NO 4 and SEQ ID NO 5; the heavy chain variable region has the nucleotide sequence of SEQ ID NO.6 and the amino acid sequence of SEQ ID NO. 7, and the heavy chain hypervariable region has the nucleotide sequence of SEQ ID NO. 8, the amino acid sequence of SEQ ID NO. 9 and the amino acid sequence of SEQ ID NO. 10. The antibody is capable of specifically binding to Yersinia pestis antigen (F1).
Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
PURPOSE: Novel therapies for diabetes have potent effects on glycemic control, obesity, and cardiovascular risk reduction, but some, including the popular drug semaglutide, have also been implicated in worsening of diabetic retinopathy (DR). Given the ubiquity of these new agents, understanding the risks to vision is important. Here, we review the data for several newly available agents in terms of systemic efficacy and retinal safety.
METHODS: Literature review.
RESULTS: Novel antihyperglycemic treatments include incretin mimetics and enhancers, sodium-glucose cotransporter inhibitors, long-acting insulins, and insulin delivery systems. All improve glycemic control, and some have been shown to reduce major cardiovascular outcomes. In a pivotal trial, semaglutide was associated with approximately 75% increased risk of DR worsening. The novel long-acting insulin icodec, formulated for once weekly dosing, showed increased risk of DR worsening over a once daily insulin. No other recent antihyperglycemic agent was associated with DR worsening, although following the semaglutide trials, nearly all studies excluded patients with preexisting DR. Cases of DR worsening were rare in all instances. Dedicated safety studies for semaglutide in DR are currently underway.
CONCLUSION: For most patients being considered for treatment with a novel antihyperglycemic agent, benefits on systemic metabolic and cardiovascular health are very likely to outweigh potential retinal harms. Although the true risks of the new agents on DR are unclear because their safety data come from secondary end points, the most vulnerable patients are those with preexisting high-risk DR, poor baseline glycemic control, and using insulin.
A genetic engineering antibody combined with a specificity of B lymphocyte stimulator (Blys), a pharmaceutical composition containing the antibody, and a kit. A heavy chain variable region of the genetic engineering antibody contains amino acid sequences shown by SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3, or a light chain variable region of the genetic engineering antibody contains amino acid sequences shown by SEQ ID NO. 4, SEQ ID NO. 5, and SEQ ID NO. 6. The present invention further provides an anti-Blys monoclonal antibody, generated by a cell line with a preservation number being CGMCC No.7352.
The present invention provides poly-substituted flavane thiadiazole compounds. In the preparing method of the poly-substitution flavane thiadiazole compound, substituted O-hydroxy acetophenone and aromatic aldehyde are used as raw materials to prepare a flavane compound III by condensation and cyclization; the obtained flavane compound is condensed with substituted benzene hydrazine to obtain substituted flavane-4-phenylhydrazone IV and V; the phenylhydrazone is cyclized with thionyl chloride, and then treated by ethanol to obtain poly-substituted flavane thiadiazole compounds VI and VII; then the compound VI can be used to prepare the other flavane thiadiazole compound VIII by reductive acylation. The poly-substituted flavane thiadiazole compounds provided by the present invention have a function for inhibiting the proliferation of various tumor cell strains, and have an in-vitro inhibiting function on tumor cells. The anti-tumor activity of the poly-substituted flavane thiadiazole compounds is larger than that of a parent compound (flavanone). The present invention has in-vivo anti-tumor activity, and is applied to the preparation of anti-tumor medicines. The structural general formula of the present invention is shown as the formula in specifications, wherein a ring A can be no-substituted, single-substituted or poly-substituted; R1 is H, Cl, CH3O-or CH3-; a ring B can be no-substituted, single-substituted or poly-substituted; R2 is H, Cl, CH3O-, CH3-or-OCH2O-; R3 is NO2-, CH3SO2-or CH3CONH-; R4 is CH3-, CH3CH2-, CH3CH2CH2-or (CH3)2CH-.
Patients with heart valve diseases often have chronic cardiac insufficiency. Patients undergoing heart valve replacement with CPB are always complicated with gastrointestinal tract ischemia-reperfusion injury, which usually leads to AGI. AGI after cardiovascular surgery, especially in that use CPB, is associated with significant morbidity and an increase in peri-operative mortality. Prolonged CPB time could be predictive of AGI following heart valve replacement. This study is to analyze the correlation between CPB time and AGI, and the outcomes of AGI in patients undergoing heart valve replacement. The investigators hope that the benefits will include fewer patients becoming seriously postoperative AGI and mortality after cardiac surgery.
PURPOSE: Initially introduced as a safer alternative to smoking, electronic cigarettes (e-cigarettes) and vaping have since been associated with lung injury. Nevertheless, there is limited perioperative data on their potential contribution to the harmful effects of mechanical ventilation on the lungs. We hypothesized that, in adults undergoing noncardiothoracic surgeries, preoperative vaping/e-cigarette use is associated with hypoxemia during the first postoperative hour, and with an increased incidence of intraoperative and postoperative pulmonary complications.
METHODS: We conducted a retrospective cohort study in which we included patients reporting as vapers/e-cigarette users within one year before surgery as the exposure group, and nonvapers as the control group. The primary outcome was the time-weighted average (TWA) SpO2/FIO2 ratio in the postanesthesia care unit during the first postoperative hour. The secondary outcome was a composite of intraoperative and postoperative pulmonary complications until discharge. We used entropy balancing to adjust for confounding, and fit weighted linear regression and logistic regression models to estimate treatment effects.
RESULTS: A total of 110,940 patients met the inclusion criteria, and 1,941 of these were vapers/e-cigarette users. The average treatment effect on the treated for TWA SpO2/FIO2 ratio (N = 109,217) was estimated to be a mean difference of 4 (95% confidence interval [CI], 1 to 8; P = 0.007). This is equivalent to a 4% change in SpO2 at a 30% FIO2 (or at a fixed FIO2). The difference was statistically significant. The average treatment effect on the treated for experiencing intraoperative and postoperative pulmonary complications (N = 110,940) was an odds ratio of 1.04 (95% CI, 0.71 to 1.54; P = 0.84).
CONCLUSION: Vaping/e-cigarette use was neither associated with clinically significant hypoxemia during the first hour in the postanesthesia care unit nor with an increase in pulmonary complications. Nevertheless, our findings cannot definitively exclude the deleterious effects of vaping and e-cigarette use on the lungs, and anesthesiologists should consider potential perioperative complications.